Nomad Foods Q3 2026: Organic Growth Turns Positive, EBITDA Still Under Pressure

What happened

Nomad Foods reported third-quarter 2026 revenue of €717 million, up 2.3% year-over-year, with organic growth of 1.6% and a 0.7% tailwind from currency. This marks a return to positive organic growth after a challenging 2025, driven by retail sell-out returning to positive territory and stabilizing volume trends. However, adjusted EBITDA declined modestly compared to the prior year, as inflation and the restoration of incentive compensation expenses offset top-line gains. Management's commentary on the earnings call likely emphasized the improved demand environment and ongoing efficiency programs, but the profitability decline suggests margin recovery remains incomplete. The result is incrementally positive versus the prior thesis of prolonged negative organic growth, though the lack of EBITDA growth tempers enthusiasm.

Implication

The return to positive organic growth, even modest at 1.6%, reduces the probability of the bear-case scenario where Nomad continues to lose share and revenue declines persist. However, the modest decline in adjusted EBITDA indicates that the company is still absorbing higher costs and not yet translating revenue growth into profit growth, so the margin recovery story remains unproven. The efficiency program and price increases are expected to help margins in 2026-2027, but execution risk remains high given past control weaknesses and exceptional charges. Given the stock's depressed valuation (~7.6x trailing EPS at last report) and 5-6% dividend yield, even flat-to-low single-digit organic growth with gradual margin improvement could support double-digit total returns. Nevertheless, investors should demand evidence of gross margin improvement and EBITDA growth in subsequent quarters before becoming more constructive, as the current quarter still lacks clear profit momentum.

Thesis delta

The previous investment thesis assumed organic revenue would stabilize at flat-to-low-single-digit growth; Q3 2026's +1.6% organic growth is consistent with that assumption but not yet a strong confirmation. The thesis has not shifted materially; it remains contingent on gross margin recovery through efficiency savings and pricing, which has not yet materialized in EBITDA terms. Confidence increases slightly that revenue declines have bottomed, but the critical margin inflection point remains unproven, so the overall conviction stays at 'potential buy' with a hold bias.